Literature DB >> 28983810

Dysregulation of Innate Lymphoid Cells in Common Variable Immunodeficiency.

Paul J Maglione1, Montserrat Cols2, Charlotte Cunningham-Rundles3.   

Abstract

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immune deficiency. With widespread use of immunoglobulin replacement therapy, non-infectious complications, such as autoimmunity, chronic intestinal inflammation, and lung disease, have replaced infections as the major cause of morbidity and mortality in this immune deficiency. The pathogenic mechanisms that underlie the development of these complications in CVID are not known; however, there have been numerous associated laboratory findings. Among the most intriguing of these associations is elevation of interferon signature genes in CVID patients with inflammatory/autoimmune complications, as a similar gene expression profile is found in systemic lupus erythematosus and other chronic inflammatory diseases. Linked with this heightened interferon signature in CVID is an expansion of circulating IFN-γ-producing innate lymphoid cells. Innate lymphoid cells are key regulators of both protective and pathogenic immune responses that have been extensively studied in recent years. Further exploration of innate lymphoid cell biology in CVID may uncover key mechanisms underlying the development of inflammatory complications in these patients and may inspire much needed novel therapeutic approaches.

Entities:  

Keywords:  Common variable immunodeficiency; Inflammatory bowel disease; Innate lymphoid cells; Lung disease; Mucosal immunology

Mesh:

Substances:

Year:  2017        PMID: 28983810      PMCID: PMC5897894          DOI: 10.1007/s11882-017-0746-6

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  109 in total

1.  Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease.

Authors:  J Marius Munneke; Andreas T Björklund; Jenny M Mjösberg; Karin Garming-Legert; Jochem H Bernink; Bianca Blom; Cynthia Huisman; Marinus H J van Oers; Hergen Spits; Karl-Johan Malmberg; Mette D Hazenberg
Journal:  Blood       Date:  2014-05-22       Impact factor: 22.113

2.  Frequency and expression of inhibitory markers of CD4(+) CD25(+) FOXP3(+) regulatory T cells in patients with common variable immunodeficiency.

Authors:  N Arandi; A Mirshafiey; H Abolhassani; M Jeddi-Tehrani; R Edalat; B Sadeghi; M Shaghaghi; A Aghamohammadi
Journal:  Scand J Immunol       Date:  2013-05       Impact factor: 3.487

Review 3.  Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis.

Authors:  Christoph S N Klose; David Artis
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

Review 4.  Group 2 innate lymphoid cells in the regulation of immune responses.

Authors:  Ben Roediger; Wolfgang Weninger
Journal:  Adv Immunol       Date:  2014-12-02       Impact factor: 3.543

Review 5.  Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment.

Authors:  Markus G Seidel
Journal:  Blood       Date:  2014-08-27       Impact factor: 22.113

Review 6.  Update on innate lymphoid cells in atopic and non-atopic inflammation in the airways and skin.

Authors:  J Mjösberg; L Eidsmo
Journal:  Clin Exp Allergy       Date:  2014-08       Impact factor: 5.018

Review 7.  The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.

Authors:  Rimma Goldberg; Natalie Prescott; Graham M Lord; Thomas T MacDonald; Nick Powell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05       Impact factor: 46.802

8.  The Incidence and Prevalence of Common Variable Immunodeficiency Disease in Taiwan, A Population-Based Study.

Authors:  Chih-Wei Tseng; Kuo-Lung Lai; Der-Yuan Chen; Ching-Heng Lin; Hsin-Hua Chen
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

Review 9.  Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway.

Authors:  Shereen Oon; Nicholas J Wilson; Ian Wicks
Journal:  Clin Transl Immunology       Date:  2016-05-13

10.  Phenotypic and functional features of human Th17 cells.

Authors:  Francesco Annunziato; Lorenzo Cosmi; Veronica Santarlasci; Laura Maggi; Francesco Liotta; Benedetta Mazzinghi; Eliana Parente; Lucia Filì; Simona Ferri; Francesca Frosali; Francesco Giudici; Paola Romagnani; Paola Parronchi; Francesco Tonelli; Enrico Maggi; Sergio Romagnani
Journal:  J Exp Med       Date:  2007-07-16       Impact factor: 14.307

View more
  4 in total

1.  Raised Serum Markers of T Cell Activation and Exhaustion in Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency.

Authors:  Mai Sasaki Aanensen Fraz; Annika Elisabet Michelsen; Natasha Moe; Trond Mogens Aaløkken; Magnhild Eide Macpherson; Ingvild Nordøy; Pål Aukrust; Eli Taraldsrud; Are Martin Holm; Thor Ueland; Silje Fjellgård Jørgensen; Børre Fevang
Journal:  J Clin Immunol       Date:  2022-07-05       Impact factor: 8.542

2.  T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.

Authors:  Federica Pulvirenti; Stefano Di Cecca; Matilde Sinibaldi; Eva Piano Mortari; Sara Terreri; Christian Albano; Marika Guercio; Eleonora Sculco; Cinzia Milito; Simona Ferrari; Franco Locatelli; Concetta Quintarelli; Rita Carsetti; Isabella Quinti
Journal:  Cells       Date:  2022-06-14       Impact factor: 7.666

3.  The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.

Authors:  Isabella Quinti; Franco Locatelli; Rita Carsetti
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

4.  Identification of Novel Genetic Variants in CVID Patients With Autoimmunity, Autoinflammation, or Malignancy.

Authors:  Mette Christiansen; Rasmus Offersen; Jens Magnus Bernth Jensen; Mikkel Steen Petersen; Carsten S Larsen; Trine H Mogensen
Journal:  Front Immunol       Date:  2020-01-27       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.